GIP and type 2 diabetes mellitus: Rosenstock Rosenstock J J Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Lancet Lancet 2021 2021 398 398 10295 10295 143 143 155 155 10.1016/S0140-6736(21)01324-6 10.1016/S0140-6736(21)01324-6 supplied-pmid 34186022?